Free Newsletter
Who should Pfizer buy?
Biogen Idec's sudden step onto the sale block has set off a frenzy of buyout talk. Will Pfizer buy it? According to the Wall Street Journal, Pfizer considered a Biogen deal two years ago and passed. What about Biogen's crosstown rival Genzyme, whose stock jumped on the Biogen news because it's a biotech ripe for Big Pharma plucking? It might be a better fit for Pfizer, some analysts say. Pfizer, of course, isn't talking.
- here's more about Pfizer's pass on Biogen two years ago
- check out this speculation about a Pfizer-Genzyme marriage
ALSO: Who will buy Biogen Idec? Poll
Related Articles:
Biogen Idec in play after Icahn makes his move. Report
Boston officials herald big Genzyme expansion. Report
Pfizer-Sanofi match not made in heaven? Report
Pfizer, Wyeth merger bad idea? Report
Read more on: Pfizer | Biogen Idec | Genzyme
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: